Keywords: lilly, gemzar, breast, cancer, treatment, eli, gemcitabine
Lilly's Gemzar as a breast cancer treatment
Article | 22 May 2001
Eli Lilly's Gemzar (gemcitabine) has been found in two Phase II clinicaltrials of women with previously-treated refractory metastatic breast cancer ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
